Sarcoma  >>  Tasigna (nilotinib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tasigna (nilotinib) / Novartis, Inhibikase
NCT00135005 / 2005-000561-18: Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Completed
1
59
Europe, US
AMN107, STI571
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
11/06
11/06
NCT00441155: Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Completed
1
14
US, Europe
Nilotinib, Imatinib
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
01/11
01/11

Download Options